What is the Best Strategy for Targeting EGF Receptors in Non-Small-Cell Lung Cancer?

References

• Azzoli CG , TeminS, AliffTet al. 2011 focused update of 2009 American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J. Clin. Oncol.29(28), 3825–3831 (2011).
   PubMed Web of Science ®Google Scholar
• Azzoli CG , BakerSJr, TeminSet al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J. Clin. Oncol.27(36), 6251–6266 (2009).
   PubMed Web of Science ®Google Scholar
• Scagliotti GV , ParikhP, Von PawelJet al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J. Clin. Oncol.26(21), 3543–3551 (2008).
   PubMed Web of Science ®Google Scholar
• Fossella F , PereiraJR, Von PawelJet al. Randomized, multinational, Phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J. Clin. Oncol.21(16), 3016–3024 (2003).
   PubMed Web of Science ®Google Scholar
• Wang T , NelsonRA, BogardusA, GrannisFWJr. Five-year lung cancer survival: which advanced stage nonsmall cell lung cancer patients attain long-term survival?Cancer116(6), 1518–1525 (2010).
   PubMed Web of Science ®Google Scholar
• Brabender J , DanenbergKD, MetzgerRet al. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin. Cancer Res.7(7), 1850–1855 (2001).
   PubMed Web of Science ®Google Scholar
• Rivera F , Vega-VillegasME, Lopez-BreaMF, MarquezR. Current situation of panitumumab, matuzumab, nimotuzumab and zalutumumab. Acta Oncol.47(1), 9–19 (2008).
   PubMed Web of Science ®Google Scholar
• Mendelsohn J . Targeting the epidermal growth factor receptor for cancer therapy. J. Clin. Oncol.20(18 Suppl.), S1–S13 (2002).
   PubMed Web of Science ®Google Scholar
• Pao W , MillerV, ZakowskiMet al. EGF receptor gene mutations are common in lung cancers from ‘never smokers’ and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl Acad. Sci. USA101(36), 13306–13311 (2004).
   PubMed Web of Science ®Google Scholar
• Hirsch FR , BunnPAJr. EGFR testing in lung cancer is ready for prime time. Lancet Oncol.10(5), 432–433 (2009).
   PubMed Web of Science ®Google Scholar
• Lynch TJ , BellDW, SordellaRet al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med.350(21), 2129–2139 (2004).
   PubMed Web of Science ®Google Scholar
• Paez JG , JannePA, LeeJCet al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science304(5676), 1497–1500 (2004).
   PubMed Web of Science ®Google Scholar
• Kosaka T , YatabeY, EndohH, KuwanoH, TakahashiT, MitsudomiT. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res.64(24), 8919–8923 (2004).
   PubMed Web of Science ®Google Scholar
• Riely GJ , PolitiKA, MillerVA, PaoW. Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin. Cancer Res.12(24), 7232–7241 (2006).
   PubMed Web of Science ®Google Scholar
• Choong NW , SalgiaR, VokesEE. Key signaling pathways and targets in lung cancer therapy. Clin. Lung Cancer8(Suppl. 2), S52–S60 (2007).
   PubMedGoogle Scholar
• Rosell R , MoranT, QueraltCet al. Screening for epidermal growth factor receptor mutations in lung cancer. N. Engl. J. Med.361(10), 958–967 (2009).
   PubMed Web of Science ®Google Scholar
• Genentech . Full prescribing information erlotinib (TARCEVA®) (2012). www.gene.com
   Google Scholar
• Roche Pharma AG . Summary of product characteristics erlotinib (TARCEVA®) (2010). www.europarl.europa.eu
   Google Scholar
• AstraZeneca AB . Summary of product characteristics gefitinib (IRESSA®) (2009). http://ec.europa.eu
   Google Scholar
• Gao G , RenS, LiAet al. Epidermal growth factor receptor tyrosine kinase inhibitor therapy is effective as first-line treatment of advanced non-small-cell lung cancer with mutated EGFR: a meta-analysis from six Phase III randomized controlled trials. Int. J. Cancer131, E822–E829 (2012).
   PubMed Web of Science ®Google Scholar
• Rosell R , CarcerenyE, GervaisRet al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised Phase 3 trial. Lancet Oncol.13(3), 239–246 (2012).
   PubMed Web of Science ®Google Scholar
• Zhou C , WuYL, ChenGet al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, Phase 3 study. Lancet Oncol.12(8), 735–742 (2011).
   PubMed Web of Science ®Google Scholar
• Mok TS , WuYL, ThongprasertSet al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med.361(10), 947–957 (2009).
   PubMed Web of Science ®Google Scholar
• Douillard J-Y , OstorosG, CoboMet al. Efficacy, safety and tolerability results from a Phase IV, open-label, single arm study of 1st-line gefitinib in Caucasian patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer. Presented at:European Multidisciplinary Conference in Thoracic Oncology (EMCTO).Lugano, Switzerland, 9–11 May 2013.
   Google Scholar
• Gatzemeier U , PluzanskaA, SzczesnaAet al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J. Clin. Oncol.25(12), 1545–1552 (2007).
   PubMed Web of Science ®Google Scholar
• Herbst RS , PragerD, HermannRet al. TRIBUTE: a Phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J. Clin. Oncol.23(25), 5892–5899 (2005).
   PubMed Web of Science ®Google Scholar
• Giaccone G , HerbstRS, ManegoldCet al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a Phase III trial – INTACT 1. J. Clin. Oncol.22(5), 777–784 (2004).
   PubMed Web of Science ®Google Scholar
• Herbst RS , GiacconeG, SchillerJHet al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a Phase III trial – INTACT 2. J. Clin. Oncol.22(5), 785–794 (2004).
   PubMed Web of Science ®Google Scholar
• Janne PA , WangX, SocinskiMAet al. Randomized Phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial. J. Clin. Oncol.30(17), 2063–2069 (2012).
   PubMed Web of Science ®Google Scholar
• Shepherd FA , Rodrigues PereiraJ, CiuleanuTet al. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med.353(2), 123–132 (2005).
   PubMed Web of Science ®Google Scholar
• Zhu CQ , Da Cunha SantosG, DingKet al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group study BR.21. J. Clin. Oncol.26(26), 4268–4275 (2008).
   PubMed Web of Science ®Google Scholar
• Garassino MC , MartelliO, BrogginiMet al. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol.14(10), 981–988 (2013).
   PubMed Web of Science ®Google Scholar
• Thatcher N , ChangA, ParikhPet al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet366(9496), 1527–1537 (2005).
   PubMed Web of Science ®Google Scholar
• Kim ES , HirshV, MokTet al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised Phase III trial. Lancet372(9652), 1809–1818 (2008).
   PubMed Web of Science ®Google Scholar
• Tan D , DeebG, WangJet al. HER-2/neu protein expression and gene alteration in stage I-IIIA non-small-cell lung cancer: a study of 140 cases using a combination of high throughput tissue microarray, immunohistochemistry, and fluorescent in situ hybridization. Diagn. Mol. Pathol.12(4), 201–211 (2003).
   PubMedGoogle Scholar
• Nguyen KS , KobayashiS, CostaDB. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin. Lung Cancer10(4), 281–289 (2009).
   PubMed Web of Science ®Google Scholar
• Metro G , CrinoL. The LUX-Lung clinical trial program of afatinib for non-small-cell lung cancer. Expert Rev. Anticancer Ther.11(5), 673–682 (2011).
   PubMed Web of Science ®Google Scholar
• Miller VA , HirshV, CadranelJet al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a Phase 2b/3 randomised trial. Lancet Oncol.13(5), 528–538 (2012).
   PubMed Web of Science ®Google Scholar
• Yang JC , ShihJY, SuWCet al. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a Phase 2 trial. Lancet Oncol.13(5), 539–548 (2012).
   PubMed Web of Science ®Google Scholar
• Sequist LV , YangJC, YamamotoNet al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J. Clin. Oncol.31(27), 3327–3334 (2013).
   PubMed Web of Science ®Google Scholar
• Yang JC , SchulerMH, YamamotoNet al. LUX-Lung 3: a randomized, open-label, Phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. Presented at: 48th Annual Meeting of the American Society of Clinical Oncology.Chicago, IL, USA, 1–5 June 2012.
   Google Scholar
• Katakami N , AtagiS, GotoKet al. LUX-Lung 4: a Phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both. J. Clin. Oncol.31(27), 3335–3341 (2013).
   PubMed Web of Science ®Google Scholar
• Wu YL , ZhouC, HuCPet al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised Phase 3 trial. Lancet Oncol.15(2), 213–222 (2014).
   PubMed Web of Science ®Google Scholar
• Lee JS , HirshV, ParkKet al. Vandetanib versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind Phase III trial (ZEPHYR). J. Clin. Oncol.30(10), 1114–1121 (2012).
   PubMed Web of Science ®Google Scholar
• Herbst RS , SunY, EberhardtWEet al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, Phase 3 trial. Lancet Oncol.11(7), 619–626 (2010).
   PubMed Web of Science ®Google Scholar
• Natale RB , ThongprasertS, GrecoFAet al. Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer. J. Clin. Oncol.29(8), 1059–1066 (2011).
   PubMed Web of Science ®Google Scholar
• De Boer RH , ArrietaO, YangCHet al. Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind Phase III trial. J. Clin. Oncol.29(8), 1067–1074 (2011).
   PubMed Web of Science ®Google Scholar
• Ross HJ , BlumenscheinGRJr, AisnerJet al. Randomized Phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer. Clin. Cancer Res.16(6), 1938–1949 (2010).
   PubMed Web of Science ®Google Scholar
• Sequist LV , BesseB, LynchTJet al. Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a Phase II trial in patients with advanced non-small-cell lung cancer. J. Clin. Oncol.28(18), 3076–3083 (2010).
   PubMed Web of Science ®Google Scholar
• Ramalingam SS , BlackhallF, KrzakowskiMet al. Randomized Phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer. J. Clin. Oncol.30(27), 3337–3344 (2012).
   PubMed Web of Science ®Google Scholar
• Mok T , KrisM, OuSet al. Efficacy, safety, and patient-reported outcomes of first-line dacomitinib (PF-00299804), an irreversible pan-her tyrosine kinase inhibitor, in patients with lung cancers harboring EGFR exon 21 mutation or EGFR exon 19 deletion. Presented at: 5th Asia Pacific Lung Cancer Conference.Fukuoka, Japan, 25–28 November 2012.
   Google Scholar
• Mok T , NakagawaK, RosellRet al. Phase III randomized, open label study (ARCHER 1050) of first-line dacomitinib (D) versus gefitinib (G) for advanced (adv) non-small cell lung cancer (NSCLC) in patients (pts) with epidermal growth factor receptor (EGFR) activating mutation(s). Presented at: 49th Annual Meeting of the American Society of Clinical Oncology.Chicago, IL, USA, 31 May–4 June 2013.
   Google Scholar
• Boehringer Ingelheim . A randomised, open-label Phase IIb trial of afatinib versus gefitinib as first-line treatment of patients with EGFR mutation positive advanced adenocarcinoma of the lung (2014). http://clinicaltrials.gov/show/NCT01466660
   Google Scholar
• Bristol-Myers Squibb . A double-blind, randomized, parallel two-arm Phase II trial of BMS-690514 versus erlotinib in previously treated NSCLC patients (2013). http://clinicaltrials.gov
   Google Scholar
• Wyeth . A Phase 2 study of EKB-569 in subjects with advanced non-small cell lung cancer (2009). http://clinicaltrials.gov
   Google Scholar
• Schuler MH , YangC-H, ParkKet al. Continuation of afatinib beyond progression: results of a randomized, open-label, Phase III trial of afatanib plus paclitaxel versus investigator’s choice chemotherapy in patients with metastatic non-small cell lung cancer progressed on erlotinib/gefitinib and afatanib – LUX-Lung 5. Presented at: 50th Annual Meeting of the American Society of Clinical Oncology.Chicago, IL, USA, 30 May–3 June 2014.
   Google Scholar
• Boehringer Ingelheim. LUX-Lung 8: A randomized, open-label Phase III trial of afatinib versus erlotinib in patients with advanced squamous cell carcinoma of the lung as second-line therapy following first-line platinum-based chemotherapy (2014). http://clinicaltrials.gov/show/NCT01523587
   Google Scholar
• Ramalingam SS , JannePA, MokTet al. Randomized, double-blinded study of dacomitinib, an irreversible panhuman epidermal growth factor receptor (HER) inhibitor, versus erlotinib for second-line/third-line therapy of locally advanced/metastatic non-small cell lung cancer (ARCHER 1009). Presented at: 50th Annual Meeting of the American Society of Clinical Oncology.Chicago, IL, USA, 30 May–3 June 2014.
   Google Scholar
• Ellis PM , LiuG, MillwardMet al. NCIC CTG BR.26: a Phase III randomized, double blind, placebo controlled trial of dacomitinib versus placebo in patients with advanced/metastatic non-small cell lung cancer (NSCLC) who received prior chemotherapy and an EGFR TKI. Presented at: 50th Annual Meeting of the American Society of Clinical Oncology.Chicago, IL, USA, 30 May–3 June 2014.
   Google Scholar
• Boehringer Ingelheim Pharmaceuticals . Full prescribing information afatinib (GILOTRIF™) (2013). www.accessdata.fda.gov
   Google Scholar
• Janjigian YY , GroenHJ, HornLet al. Activity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinib. Presented at: 47th Annual Meeting of the American Society of Clinical Oncology.Chicago, IL, USA, 3–6 June 2011.
   Google Scholar
• Janjigian YY , SmitEF, HornLet al. Activity of afatinib/cetuximab in patients with EGFR mutant non-small cell lung cancer and acquired resistance to EGFR inhibitors. Presented at: 37th European Society of Medical Oncology Congress.Vienna, Austria, 28 September–2 October 2012.
   Google Scholar
• Keedy VL , TeminS, SomerfieldMRet al. American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J. Clin. Oncol.29(15), 2121–2127 (2011).
   PubMed Web of Science ®Google Scholar
• Pirker R , HerthFJ, KerrKMet al. Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. J. Thorac. Oncol.5(10), 1706–1713 (2010).
   PubMedGoogle Scholar
• D’addario G , FruhM, ReckM, BaumannP, KlepetkoW, FelipE. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol.21(Suppl. 5), v116–v119 (2010).
   PubMed Web of Science ®Google Scholar
• Felip E , GarridoP, TrigoJMet al. SEOM guidelines for the management of non-small-cell lung cancer (NSCLC). Clin. Transl. Oncol.11(5), 284–289 (2009).
   PubMed Web of Science ®Google Scholar
• Lazzari C , NovelloS, BarniSet al. Randomized proteomic stratified Phase III study of second-line erlotinib versus chemotherapy in patients with inoperable non-small cell lung cancer (PROSE). Presented at: 49th Annual Meeting of the American Society of Clinical Oncology.Chicago, IL, USA, 31 May-4 June 2013.
   Google Scholar
• ImClone LLC . Full prescribing information ERBITUX® (cetuximab) (2013). http://packageinserts.bms.com/pi/pi_erbitux.pdf
   Google Scholar
• Pirker R , PereiraJR, SzczesnaAet al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised Phase III trial. Lancet373(9674), 1525–1531 (2009).
   PubMed Web of Science ®Google Scholar
• Pirker R , PereiraJR, Von PawelJet al. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the Phase 3 FLEX study. Lancet Oncol.13(1), 33–42 (2012).
   PubMed Web of Science ®Google Scholar
• Lynch TJ , PatelT, DreisbachLet al. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter Phase III trial BMS099. J. Clin. Oncol.28(6), 911–917 (2010).
   PubMed Web of Science ®Google Scholar
• Crawford J , SandlerAB, HammondLAet al. ABX-EGF in combination with paclitaxel and carboplatin for advanced non-small cell lung cancer (NSCLC). Presented at: 40th Annual Meeting of the American Society of Clinical Oncology.Chicago, IL, USA, 5–8 June 2004.
   Google Scholar
• Mekhail T , WaterhouseDM, HadleyTJet al. First-line carboplatin, pemetrexed, and panitumumab in patients with advanced nonsquamous KRAS wild type non-small cell lung cancer. Presented at: 49th Annual Meeting of the American Society of Clinical Oncology.Chicago, IL, USA, 31 May–4 June 2013.
   Google Scholar
• Prabhash K , BabuKG, VaidAKet al. Nimotuzumab plus chemotherapy versus chemotherapy alone in advanced non-small cell lung cancer: a Phase II, open-label, multicenter, randomized study. Presented at: 49th Annual Meeting of the American Society of Clinical Oncology.Chicago, IL, USA, 31 May–4 June 2013.
   Google Scholar
• Paz-Ares L , MiziaraJE, LosonczyGet al. Randomized Phase-3 trial (INSPIRE) of necitumumab plus cisplatin–pemetrexed versus cisplatin–pemetrexed alone as first-line therapy in stage IV non-squamous NSCLC. Presented at: 15th World Congress on Lung Cancer.Sydney, Australia, 27–30 October 2013.
   Google Scholar
• Daiichi Sankyo Company, Ltd . Daiichi Sankyo enrolls first patient in nimotuzumab Phase 3 clinical trials (2013). www.daiichisankyo.com
   Google Scholar
• Thatcher N , HirschFR, SzczesnaAet al. A randomized, multicenter, open-label, Phase III study of gemcitabine-cisplatin chemotherapy plus necitumumab (IMC-11F8/LY3012211) versus gemcitabine-cisplatin alone in the first-line treatment of patients with stage IV squamous non-small cell lung cancer. Presented at: 50th Annual Meeting of the American Society of Clinical Oncology.Chicago, IL, USA, 30 May–3 June 2014.
   Google Scholar
• Kurai J , ChikumiH, HashimotoKet al. Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines. Clin. Cancer Res.13(5), 1552–1561 (2007).
   PubMed Web of Science ®Google Scholar
• Rosell R , RobinetG, SzczesnaAet al. Randomized Phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. Ann. Oncol.19(2), 362–369 (2008).
   PubMed Web of Science ®Google Scholar
• Butts CA , BodkinD, MiddlemanELet al. Randomized Phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer. J. Clin. Oncol.25(36), 5777–5784 (2007).
   PubMed Web of Science ®Google Scholar
• Lynch T , BhagavatheeswaranP, MukhopadhyayP, Khambata-FordS, HarbisonCT. A retrospective subgroup analysis of EGFR immunohistochemistry (IHC) expression by histo-score correlated to outcomes from the BMS099 1st line Phase III NSCLC trial of cetuximab (Cet) plus carboplatin/taxane. Eur. J. Cancer47(Suppl. 1), 591–592 (2011).
   Google Scholar
• O’Byrne KJ , GatzemeierU, BondarenkoIet al. Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the Phase 3 FLEX study. Lancet Oncol.12(8), 795–805 (2011).
   PubMed Web of Science ®Google Scholar
• Khambata-Ford S , HarbisonCT, HartLLet al. Analysis of potential predictive markers of cetuximab benefit in BMS099, a Phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer. J. Clin. Oncol.28(6), 918–927 (2010).
   PubMed Web of Science ®Google Scholar
• Gatzemeier U , Von PawelJ, VynnychenkoIet al. First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX Phase 3 study. Lancet Oncol.12(1), 30–37 (2011).
   PubMed Web of Science ®Google Scholar
• Foon KA , YangXD, WeinerLMet al. Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int. J. Radiat. Oncol. Biol. Phys.58(3), 984–990 (2004).
   PubMed Web of Science ®Google Scholar
• Freeman DJ , BushT, OgbagabrielSet al. Activity of panitumumab alone or with chemotherapy in non-small cell lung carcinoma cell lines expressing mutant epidermal growth factor receptor. Mol. Cancer Ther.8(6), 1536–1546 (2009).
   PubMed Web of Science ®Google Scholar
• Amgen, Inc . Full prescribing information panitumumab (VECTIBIX®) (2009). www.accessdata.fda.gov
   Google Scholar
• Socinski MA . Antibodies to the epidermal growth factor receptor in non small cell lung cancer: current status of matuzumab and panitumumab. Clin. Cancer Res.13(15 Pt 2), s4597–s4601 (2007).
   PubMed Web of Science ®Google Scholar
• Topper MB , TonraJR, PytowskiB, EastmanSW. Differentiation between the EGFR antibodies necitumumab, cetuximab, and panitumumab: antibody internalization and EGFR degradation. Presented at: 47th Annual Meeting of the American Society of Clinical Oncology.Chicago, IL, USA, 3–6 June 2011.
   Google Scholar
• Patel D , SaxenaB, ZhouQet al. Differential induction of antibody-dependent cellular cytotoxicity (ADCC) against human EGFR-expressing NSCLC cell lines by necitumumab, cetuximab, and panitumumab. 47th Annual Meeting of the American Society of Clinical Oncology.Chicago, IL, USA, 3–6 June 2011.
   Google Scholar
• Samakoglu S , DeeviDS, LiHet al. Preclinical rationale for combining an EGFR antibody with cisplatin/gemcitabine for the treatment of NSCLC. Cancer Genomics Proteomics9(2), 77–92 (2012).
   PubMed Web of Science ®Google Scholar
• Sharma SV , BellDW, SettlemanJ, HaberDA. Epidermal growth factor receptor mutations in lung cancer. Nat. Rev. Cancer7(3), 169–181 (2007).
   PubMed Web of Science ®Google Scholar
• Bahleda R , SoriaJ, HarbisonCet al. Tumor regression and pharmacodynamic (PD) biomarker validation in non-small cell lung cancer (NSCLC) patients treated with the ErbB/VEGFR inhibitor BMS-690514. Presented at: 45th Annual Meeting of the American Society of Clinical Oncology.Chicago, IL, USA, 29 May–2 June 2009.
   Google Scholar
• Yoshimura N , KudohS, KimuraTet al. EKB-569, a new irreversible epidermal growth factor receptor tyrosine kinase inhibitor, with clinical activity in patients with non-small cell lung cancer with acquired resistance to gefitinib. Lung Cancer51(3), 363–368 (2006).
   PubMed Web of Science ®Google Scholar
• Janne PA , RamalingamSS, YangJC-Het al. Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients with EGFR inhibitor-resistant non-small cell lung cancer. Presented at: 50th Annual Meeting of the American Society of Clinical Oncology.Chicago, IL, USA, 30 May–3 June 2014.
   Google Scholar
• Sequist L , SoriaJ-C, GadgeelSet al. First-in-human evaluation of CO-1686, an irreversible, highly selective tyrosine kinase inhibitor of mutations of EGFR (activating and T790M). Presented at: 50th Annual Meeting of the American Society of Clinical Oncology.Chicago, IL, USA, 30 May–3 June 2014.
   Google Scholar
• Cappuzzo F , JannePA, SkokanMet al. MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. Ann Oncol.20(2), 298–304 (2009).
   PubMed Web of Science ®Google Scholar
• Cappuzzo F , MarchettiA, SkokanMet al. Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J. Clin. Oncol.27(10), 1667–1674 (2009).
   PubMed Web of Science ®Google Scholar
• Spigel D , ErvinT, RamlauRet al. Randomized multicenter double-blind placebo-controlled Phase II study evaluating MetMAb, an antibody to Met receptor, in combination with erlotinib, in patients with advanced non-small-cell lung cancer. Presented at: 35th European Society for Medical Oncology Congress.Milan, Italy, 8–12 October 2010.
   Google Scholar
• Sequist LV , Von PawelJ, GarmeyEGet al. Randomized Phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J. Clin. Oncol.29(24), 3307–3315 (2011).
   PubMed Web of Science ®Google Scholar
• Spigel DR , EdelmanMJ, O’ByrneKet al. Onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIb or IV NSCLC: results from the pivotal Phase III randomized, multicenter, placebo-controlled METLung (OAM4971g) global trial. Presented at: 50th Annual Meeting of the American Society of Clinical Oncology.Chicago, IL, USA, 30 May–3 June 2014.
   Google Scholar
• Scagliotti G , NovelloS, RamlauRet al. MARQUEE. A randomized, double-blind, placebo-controlled, Phase 3 trial of tivantinib (ARQ 197) plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, non-squamous, non-small-cell lung cancer. Presented at: European Cancer Congress 2013 (ECCO–ESMO–ESTRO).Amsterdam, The Netherlands, 27 September–1 October 2013.
   Google Scholar
• Novello S , ScagliottiG, RamlauRet al. Efficacy analysis for molecular subgroups in MARQUEE: a randomized, double-blind, placebo-controlled, Phase 3 trial of tivantinib (ARQ 197) plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, non-squamous, non-small cell lung cancer. Presented at: 15th World Conference on Lung Cancer.Sydney, Australia, 27–31 October 2013.
   Google Scholar
• Azuma K , YoshiokaH, YamamotoNet al. Tivantinib plus erlotinib versus placebo plus erlotinib in Asian patients with previously treated nonsquamous NSCLC with wild-type EGFR: first report of a Phase III ATTENTION trial. Presented at: 50th Annual Meeting of the American Society of Clinical Oncology.Chicago, IL, USA, 30 May–3 June 2014.
   Google Scholar